Maurie Markman, MD, president of medicine and science, Cancer Treatment Centers of America, editor-in-chief, 

, discusses endpoints in clinical trials for ovarian cancer.

Using overall survival (OS) as a primary endpoint for phase III randomized trials is no longer rational, says Markman. This endpoint assumes that what happens to a patient after they go on the trial is going to be similar for patients on either arm of the study.

Therefore, holding a drug or combination “hostage” to an OS endpoint is irrational and risky, explains Markman.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Ovarian Cancer

GSK-22-OSD1278 - /clinical/ovarian-cancer

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

PER® Chemotherapy Foundation Symposium (CFS)

Maurie Markman, MD, president of medicine and science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses endpoints in clinical trials for ovarian cancer.

Dr. Markman on Endpoints in Clinical Trials for Ovarian Cancer